https://www.businesswire.com/news/home/20260529645249/en/ASCO-2026-Bayer-Shares-New-Findings-for-NUBEQA-darolutamide-Regarding-Cognitive-Decline-in-Men-with-Advanced-Prostate-Cancer-Compared-to-Enzalutamide-in-Phase-II-ARACOG-Head-to-Head-Trial 2026-05-30T21:24:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T21:24:00.000Z ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial BAYN,BAYRY,BAYZF https://mms.businesswire.com/media/20260529645249/en/830197/21/Bayer_Logo.jpg https://www.businesswire.com/news/home/20260530804788/es 2026-05-30T19:51:00.000Z weekly 0.5 Business Wire es PressRelease 2026-05-30T19:51:00.000Z Resumen: El ensayo fundamental frontMIND de Incyte demostró que la combinación con tafasitamab (Monjuvi®/Minjuvi®) prolongó significativamente la supervivencia libre de progresión, lo que reduce en un 25 % el riesgo de progresión de la enfermedad o muerte... INCY https://mms.businesswire.com/media/20260530804788/es/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260530248381/fr 2026-05-30T19:51:00.000Z weekly 0.5 Business Wire fr PressRelease 2026-05-30T19:51:00.000Z L’essai pivot frontMIND d’Incyte a montré que l’association à base de tafasitamab (Monjuvi®/Minjuvi®) prolongeait significativement la survie sans progression, réduisant de 25 % le risque de progression de la maladie ou de décès chez les patients... INCY https://mms.businesswire.com/media/20260530248381/fr/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260530963084/it 2026-05-30T19:51:00.000Z weekly 0.5 Business Wire it PressRelease 2026-05-30T19:51:00.000Z Riassunto: frontMIND, lo studio clinico cardine di Incyte ha dimostrato come la combinazione tafasitamab (Monjuvi®/Minjuvi®) sia in grado di prolungare notevolmente la sopravvivenza libera da progressione, riducendo il rischio di progressione della malattia... INCY https://mms.businesswire.com/media/20260530963084/it/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260530204190/nl 2026-05-30T19:51:00.000Z weekly 0.5 Business Wire nl PressRelease 2026-05-30T19:51:00.000Z Samenvatting: Cruciale frontMIND-studie van Incyte heeft aangetoond dat de combinatie van tafasitamab (Monjuvi®/Minjuvi®) de progressievrije overleving significant verlengde en het risico op ziekteprogressie of overlijden met 25% verlaagde bij patiënten met... INCY https://mms.businesswire.com/media/20260530204190/nl/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260530902647/en/Salubris-Biotherapeutics-Announces-Updated-Phase-12-Data-for-JK06-a-5T4-Targeted-Antibody-Drug-Conjugate-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting 2026-05-30T18:30:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T18:30:00.000Z Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting https://mms.businesswire.com/media/20260530902647/en/2817654/21/SalubrisBio_logo_new_png.jpg https://www.businesswire.com/news/home/20260530067460/en/BW-LPG-Enters-Into-Agreement-for-Eight-90cbm-Panamax-Newbuildings-with-Hyundai-Heavy-Industries 2026-05-30T16:03:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T16:03:00.000Z BW LPG Enters Into Agreement for Eight 90’cbm Panamax Newbuildings with Hyundai Heavy Industries BWLP,BWLPG.OL https://mms.businesswire.com/media/20260530067460/en/2118887/21/BW_LPG_Logo.jpg https://www.businesswire.com/news/home/20260530475386/en/Mirum-Pharmaceuticals-Announces-New-Data-from-Rare-Liver-Disease-Programs-Presented-at-the-EASL-International-Liver-Congress-2026 2026-05-30T16:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T16:00:00.000Z Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026 MIRM https://mms.businesswire.com/media/20260530475386/en/746217/21/Mirum_Inline_FullColor_RGB.jpg https://www.businesswire.com/news/home/20260530374928/en/INVESTOR-NOTICE-Robbins-Geller-Rudman-Dowd-LLP-Announces-that-Sportradar-Group-AG-SRAD-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit 2026-05-30T15:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T15:00:00.000Z INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sportradar Group AG (SRAD) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit SRAD https://mms.businesswire.com/media/20260530374928/en/2313484/21/RGRD_Logo_2v2.jpg https://www.businesswire.com/news/home/20260530141381/en/CVLT-INVESTOR-DEADLINE-Robbins-Geller-Rudman-Dowd-LLP-Announces-that-Commvault-Systems-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit 2026-05-30T15:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T15:00:00.000Z CVLT INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Commvault Systems, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit CVLT https://mms.businesswire.com/media/20260530141381/en/2313484/21/RGRD_Logo_2v2.jpg https://www.businesswire.com/news/home/20260530932788/en/Massive-Bio-Announces-Next-Generation-Reticulum-Nexus-Product-Suite-at-ASCO-2026 2026-05-30T14:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T14:00:00.000Z Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026 https://mms.businesswire.com/media/20260530932788/en/2819276/21/MB-ASCO-PR-2.jpg https://www.businesswire.com/news/home/20260529816966/en/Exelixis-Announces-Results-from-Subgroup-Analysis-of-Phase-3-CABINET-Pivotal-Trial-Evaluating-CABOMETYX-cabozantinib-in-Non-Functional-and-Functional-Neuroendocrine-Tumors-at-ASCO-2026 2026-05-30T14:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T14:00:00.000Z Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026 EXEL https://mms.businesswire.com/media/20260529816966/en/1937209/21/2023_Exelixis_Logo.jpg https://www.businesswire.com/news/home/20260530865068/fr 2026-05-30T13:31:00.000Z weekly 0.5 Business Wire fr PressRelease 2026-05-30T13:31:00.000Z La Global Real Assets Trust publie ses résultats du premier trimestre de l’année 2026 https://mms.businesswire.com/media/20260530865068/fr/1693308/21/Starlight_Logo_Wordmark-Capital_Colour.jpg https://www.businesswire.com/news/home/20260530490588/en/Global-Real-Assets-Trust-Reports-Q1-2026-Results 2026-05-30T13:31:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T13:31:00.000Z Global Real Assets Trust Reports Q1 2026 Results https://mms.businesswire.com/media/20260530490588/en/1693308/21/Starlight_Logo_Wordmark-Capital_Colour.jpg https://www.businesswire.com/news/home/20260530598089/en/Tempus-Launches-the-PRECISION-Challenge-a-National-Program-Opening-Its-Foundation-Model-Work-to-the-Broader-Research-Community 2026-05-30T12:30:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T12:30:00.000Z Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community TEM https://mms.businesswire.com/media/20260530598089/en/566718/21/black_wordmark.jpg https://www.businesswire.com/news/home/20260530351488/en/TALZENNA-Plus-XTANDI-Improves-Radiographic-Progression-Free-Survival-by-More-Than-50-in-Metastatic-Prostate-Cancer 2026-05-30T12:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T12:00:00.000Z TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer PFE https://mms.businesswire.com/media/20260530351488/en/1045874/21/Pfizer_Logo_Color_RGB_APPROVED.jpg https://www.businesswire.com/news/home/20260530183615/en/ENZAMET-Trial-Shows-Veracytes-Decipher-Prostate-Test-Identifies-Which-Patients-Benefit-from-Adding-Chemotherapy-in-Metastatic-Prostate-Cancer 2026-05-30T12:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T12:00:00.000Z ENZAMET Trial Shows Veracyte's Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer VCYT https://mms.businesswire.com/media/20260530183615/en/791654/21/Veracyte_RGB_LRG_H_registered.jpg https://www.businesswire.com/news/home/20260530052195/en/Tune-Therapeutics-Presents-Positive-Phase-1b2a-Proof-of-Concept-Data-on-TUNE-401-a-First-in-Class-Epigenetic-Silencer-for-Patients-with-Hepatitis-B-at-EASL-2026 2026-05-30T12:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T12:00:00.000Z Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for Patients with Hepatitis B at EASL 2026 https://mms.businesswire.com/media/20260530052195/en/2818699/21/Tune_Logo_Highest_Res_NOW.jpg https://www.businesswire.com/news/home/20260530890115/en/Immunome-Announces-Detailed-Phase-3-RINGSIDE-Data-for-Varegacestat-in-Adults-with-Progressing-Desmoid-Tumors-at-the-2026-ASCO-Annual-Meeting 2026-05-30T12:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T12:00:00.000Z Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting IMNM https://mms.businesswire.com/media/20260530890115/en/2818302/21/Immunome_Logo_TM_RGB.jpg https://www.businesswire.com/news/home/20260530829355/en/Tempus-Introduces-Preview-Bridging-the-Critical-Time-Gap-Between-Diagnostic-Order-and-Definitive-Results 2026-05-30T12:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T12:00:00.000Z Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results TEM https://mms.businesswire.com/media/20260530829355/en/566718/21/black_wordmark.jpg https://www.businesswire.com/news/home/20260530544179/en/Encouraging-Global-Phase-II-Ivonescimab-Data-in-First-Line-Metastatic-Colorectal-Cancer-Presented-at-ASCO-2026 2026-05-30T12:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T12:00:00.000Z Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026 SMMT https://mms.businesswire.com/media/20260530544179/en/2208782/21/2024-Summit-logo-RGB.jpg https://www.businesswire.com/news/home/20260530259024/en/Incytes-Pivotal-frontMIND-Trial-Showed-Tafasitamab-MonjuviMinjuvi-Combination-Significantly-Prolonged-Progression-free-Survival-Reducing-the-Risk-of-Disease-Progression-or-Death-by-25-in-Patients-with-Previously-Untreated-High-risk-DLBCL 2026-05-30T12:00:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T12:00:00.000Z Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL INCY https://mms.businesswire.com/media/20260530259024/en/1078784/21/Incyte_Color_Logo_JPEG_2colorpos.jpg https://www.businesswire.com/news/home/20260529745319/en/FCPT-Announces-Agreement-to-Acquire-up-to-102-Mission-Pet-Health-Veterinary-Properties-for-%24268-Million 2026-05-30T02:20:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T02:20:00.000Z FCPT Announces Agreement to Acquire up to 102 Mission Pet Health Veterinary Properties for $268 Million FCPT https://www.businesswire.com/news/home/20260529103245/en/AVAV-INVESTOR-NOTICE-Robbins-Geller-Rudman-Dowd-LLP-Announces-that-AeroVironment-Inc.-Investors-with-Substantial-Losses-Have-Opportunity-to-Lead-Class-Action-Lawsuit 2026-05-30T02:05:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T02:05:00.000Z AVAV INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that AeroVironment, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit AVAV https://mms.businesswire.com/media/20260529103245/en/2313484/21/RGRD_Logo_2v2.jpg https://www.businesswire.com/news/home/20260528413644/es 2026-05-30T01:42:00.000Z weekly 0.5 Business Wire es PressRelease 2026-05-30T01:42:00.000Z Fortegra concreta su adquisición por parte de DB Insurance https://mms.businesswire.com/media/20260528413644/es/2817590/21/fortegra-logo-blue-v-300x129.jpg https://www.businesswire.com/news/home/20260529472902/en/Shareholder-Notice-Robbins-LLP-Informs-Investors-of-the-Lucid-Group-Inc.-Class-Action 2026-05-30T00:39:00.000Z weekly 0.5 Business Wire en PressRelease 2026-05-30T00:39:00.000Z Shareholder Notice: Robbins LLP Informs Investors of the Lucid Group, Inc. Class Action LCID https://mms.businesswire.com/media/20260529472902/en/805853/21/Robbins_LLP.jpg